Conditions that we treat

Epidemiological studies indicate that more than 20% of the population suffers from one of these diseases, in other words, 1 in 5 people. As the name suggests, these are pathologies that have multiple points of interrelation, both clinical and pathophysiological: the phenomenon of autoimmunity, shared genetic variables, and immunological alterations.

The list of diseases is extensive: systemic lupus erythematosus, cutaneous lupus, antiphospholipid syndrome, Rheumatoid Arthritis, Spondyloarthropathies, Ankylosing Spondylitis, Psoriasis, Psoriatic Arthritis, Sjögren's Syndrome or Dry Syndrome, Systemic Vasculitis, Cutaneous Vasculitis, Polymyalgia Rheumatica, Horton's Arteritis, Inflammatory Bowel Diseases: Crohn's disease, ulcerative colitis, autoimmune liver diseases, dermatomyositis, inflammatory myopathies, mixed connective tissue disease, systemic sclerosis (also known as scleroderma) – to name the most prevalent in our environment.

Each of these diseases has its own characteristics, can affect several target organs depending on the patient's genetics, and requires more thorough monitoring by the specialist involved in each case.

The consequences of these diseases are not insignificant. Although the use of immunomodulatory drugs currently allows remission of the disease in most cases and good control throughout the patient's life, the adverse effects of these medications and the sequelae of inflammation represent a significant physical and psychological burden on the patient and their daily environment, substantially affecting their quality of life and life expectancy.